XML 59 R13.htm IDEA: XBRL DOCUMENT

Segment information	12 Months Ended
Segment information	Dec. 31, 2024
Disclosure of operating segments [abstract]
Segment information	Segment information The assessment of the Group’s performance and the decisions about resources to be allocated are made by the chief operating decision maker, based on the management reporting system of the Group. The Group identified the Chief Executive Officer of the Group as “chief operating decision maker”. The chief operating decision maker reviews on an aggregated basis the incurred expenses for allocating and evaluating performance of the Group. The Group operates in a single operating segment: R&D of pharmaceutical products in order to market them in the future. Substantially all operations, assets, liabilities, and losses of the Group are located in France. As of December 31, 2023 and 2024, the U.S. Subsidiary (created in 2023) has contributions to the Group’s assets, liabilities and net losses that were less than 10%.